23 research outputs found
Impact of aging on host immune response and survival in melanoma: an analysis of 3 patient cohorts
No full textAdjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis
No full textAbstract Background Cancer-testis antigen NY-ESO-1 is a highly immunogenic melanoma antigen which has been incorporated into adjuvant vaccine clinical trials. Three such early-phase trials were conducted at our center among patients with high-risk resected melanoma. We herein report on the pooled long-term survival outcomes of these patients in comparison to historical controls. Methods All melanoma patients treated at NYU Langone Health under any of three prospective adjuvant NY-ESO-1 vaccine trials were retrospectively pooled into a single cohort. All such patients with stage III melanoma were subsequently compared to historical control patients identified via a prospective institutional database with protocol-driven follow-up. Survival times were calculated using the Kaplan-Meier method, and Cox proportional hazard models were employed to identify significant prognostic factors and control for confounding variables. Results A total of 91 patients were treated with an NY-ESO-1 vaccine for the treatment of high-risk resected melanoma. Of this group, 67 patients were stage III and were selected for comparative analysis with 123 historical control patients with resected stage III melanoma who received no adjuvant therapy. Among the pooled vaccine cohort (median follow-up 61 months), the estimated median recurrence-free survival was 45 months, while the median overall survival was not yet reached. In the control cohort of 123 patients (median follow-up 30 months), the estimated median recurrence-free and overall survival were 22 and 58 months, respectively. Within the retrospective stage III cohort, NY-ESO-1 vaccine was associated with decreased risk of recurrence (HR = 0.56, p < 0.01) and death (HR = 0.51, p = 0.01). Upon controlling for sub-stage, the adjuvant NY-ESO-1 clinical trial cohort continued to exhibit decreased risk of recurrence (HR = 0.45, p < 0.01) and death (HR = 0.40, p < 0.01). Conclusions In this small retrospective cohort of resected stage III melanoma patients, adjuvant NY-ESO-1 vaccine immunotherapy was associated with longer recurrence-free and overall survival relative to historical controls. These data support the continued investigation of adjuvant NY-ESO-1 based immunotherapy regimens in melanoma
Corrigendum to “Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma” (Hum Pathol 2016;57:116-25)
No full textAssociation between Ki-67 expression and clinical outcomes among patients with clinically node-negative, thick primary melanoma who underwent nodal staging
No full textAdjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis
No full textMOESM2 of Impact of aging on host immune response and survival in melanoma: an analysis of 3 patient cohorts
No full textAdditional file 2: Table S2. Clinicopathologic features of 84 IMCG and 43 TCGA primary melanomas in gene expression analysis
MOESM4 of Impact of aging on host immune response and survival in melanoma: an analysis of 3 patient cohorts
No full textAdditional file 4: Table S4. Immunoregulatory gene expression of 84 IMCG primary melanomas
MOESM1 of Impact of aging on host immune response and survival in melanoma: an analysis of 3 patient cohorts
No full textAdditional file 1: Table S1. A Association of SEER clinicopathologic features with age. B Association of IMCG clinicopathologic features with age and tumor infiltrating lymphocytes. C Association of TCGA clinicopathologic features with age and lymphocyte score
MOESM3 of Impact of aging on host immune response and survival in melanoma: an analysis of 3 patient cohorts
No full textAdditional file 3: Table S3. A Significant gene expression differences with aging in the IMCG primary melanoma cohort (n = 84). B Significant gene expression differences with aging in the TCGA primary melanoma cohort (n = 43)
circulating tumor DNA as a potential biomarker of disease activity in patients with unresectable stage III/IV melanoma receiving immuno-oncology therapies
No full text
